By Fineline Cube 
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced that the European Commission (EC) has adopted a decision to revoke the marketing authorisation for TAVNEOS (avacopan) across European Union (EU) and European Economic Area (EEA) countries.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | European Commission (EC) |
| Decision | Revocation of marketing authorisation |
| Product | TAVNEOS (avacopan) |
| Indication | Severe, active GPA or MPA in adult patients |
| Affected Markets | EU and EEA countries |
| Announcement Date | 18 Aug 2026 |
| Next Steps | Not specified in the announcement |
Drug Profile & Mechanism of Action
- Molecule: Avacopan, an oral small‑molecule drug.
- Mechanism: Selective inhibitor of the complement C5a receptor C5aR1.
- Regimen: Used in combination with rituximab or cyclophosphamide.
- Indication: Treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
- Origin: Originally developed by ChemoCentryx.
Commercial & Licensing Background
- Commercialisation Structure: Avacopan is commercialised outside the United States and in select countries by CSL, its affiliates and partners.
- Agreement Basis: Commercialisation proceeds under a collaboration and licensing agreement between VFMCRP and ChemoCentryx.
- U.S. Market: The revocation decision applies to EU and EEA markets; the announcement does not address the drug’s status in the United States.
Market Impact & Outlook
- Access Implications: The EC decision removes TAVNEOS from the treatment landscape for GPA and MPA patients across the EU and EEA, narrowing options for a rare, serious autoimmune condition.
- Portfolio Effect: For CSL and VFMCRP, the revocation eliminates a commercial asset in European nephrology and vasculitis markets, with implications for regional revenue and pipeline strategy.
- Regulatory Divergence: With the product’s fate now split across jurisdictions, attention turns to how the decision interacts with approvals and commercialisation in the United States and other select markets.
- Strategic Positioning: The outcome underscores the regulatory risk attached to orphan and specialist therapies, where post‑authorisation obligations can determine a product’s long‑term commercial viability.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation and consequences of the EC decision on TAVNEOS. Actual results may differ due to risks including regulatory implementation, market dynamics and competitive developments.-Fineline Info & Tech